Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma.
IFN-gamma-induced chemokines
adult-onset Still's disease
adverse events
dabrafenib plus trametinib combined therapy
sCD163
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
02
09
2020
revised:
31
10
2020
accepted:
11
11
2020
pubmed:
16
11
2020
medline:
25
5
2021
entrez:
15
11
2020
Statut:
ppublish
Résumé
Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence of pyrexia was highest among the series of AEs in patients treated with D + T combination therapy. Although little is known about the mechanisms of pyrexia caused by D + T combination therapy, a recent report suggested that sCD163, as well as interferon-inducible chemokines (CXCL9, CXCL10, CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib combination therapy. In addition to these soluble factors, CXCL5 is a biomarker for predicting immune-related AEs in melanoma patients treated with nivolumab. From the above findings, we hypothesized that these soluble factors might also correlate with the onset of AEs in D + T combination therapy. The serum levels of sCD163 were increased in patients with pyrexia in parallel with their severity, whereas the serum levels of CXCL5 were increased in patients without pyrexia. Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and activated CD8+ T cells, increased serum levels of these chemokines might correlate with the positive feedback of inflammatory reactions related to AEs.
Substances chimiques
Biomarkers
0
Chemokines
0
Imidazoles
0
Oximes
0
Pyridones
0
Pyrimidinones
0
trametinib
33E86K87QN
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
dabrafenib
QGP4HA4G1B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14544Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 19cm0106434h0002
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626-636.
Gogas HJ, Flaherty KT, Dummer R, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315-1327.
Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248-1260.
Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41.
Amagai R, Fujimura T, Kambayashi Y, et al. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. J Dermatol. 2020;47:654-657.
Han JH, Suh CH, Jung JY, et al. Elevated circulating levels of the interferon-γ-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease. Sci Rep. 2017;7:46652.
Colafrancesco S, Priori R, Alessandri C, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60:177-183.
Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010;47:1650-1660.
Kwon OC, Lee EJ, Chang EJ, et al. IL-17A(+)GM-CSF(+) neutrophils are the major infiltrating cells in interstitial lung disease in an autoimmune arthritis model. Front Immunol. 2018;9:1544.
Buckland J. Rheumatoid arthritis: citrullination alters the inflammatory properties of chemokines in inflammatory arthritis. Nat Rev Rheumatol. 2014;10:446.
Tojo G, Fujimura T, Kawano M, et al. Comparison of IL-17 producing cells in different clinical types of alopecia areata. Dermatology. 2013;227:77-82.
Fujimura T, Sato Y, Tanita K, et al. Serum soluble CD163 and CXCL5 could be predictive markers for immune related adverse event in patients with advanced melanoma treated with nivolumab. Oncotarget. 2018;9:15542-15551.
Furudate S, Fujimura T, Kakizaki A, Hidaka T, Asano M, Aiba S. Tumor-associated M2 macrophages in mycosis fungoides aquired immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci. 2016;83:182-189.
Fang S, Zhang S, Huang Y, et al. Evidence for associations between Th1/Th17 "hybrid" phenotype and altered Lipometabolism in very severe graves orbitopathy. J Clin Endocrinol Metab. 2020;105:dgaa124.
Irimada M, Fujimura T, Kambayashi Y, et al. Severe rhabdomyolysis developing from an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy. J Dermatol. 2019;46:e256-e258.